Human Stem Cells Institute OJSC (HSCI) is a Russian public biotech company founded in 2003.

HSCI is engaged in drug discovery, R&D and marketing of innovative proprietary products and services in the field of regenerative medicine, bio-insurance, medical genetics, including reproductive genetics, gene therapy and biopharmaceutics.

The Company aims to foster a new culture of medical care – developing new health care opportunities in such areas as personalized and preventive medicine.

HSCI owns the largest family cord blood stem cell bank in Russia – Gemabank, as well as the reproductive cell and tissue bank Reprobank (personal storage and donation).

The Company launched Neovasculgen®, the first-in-class gene-therapy drug for treating Peripheral Arterial Disease, including Critical Limb Ischemia, and also introduced the innovative cell technology SPRS-therapy, which entails the use of autologous dermal fibroblasts to repair skin damage due to aging and other structural changes.

HSCI is implementing a socially significant project to create its own Russia-wide network of Genetico medical centers & testing lab to provide a range of genetic diagnostic and consulting services with the aim of early identification, prediction and prophylactic treatment of genetic disorders (incl. PGD and NIPT among others).

The Company actively promotes its products on the Russian market and intends to open new markets throughout the world.

HSCI is listed on the Innovation & Investment Market (iIM) of the Moscow Exchange (ticker ISKJ). The Company conducted its IPO in December 2009, becoming the first Russian biotech company to go public.

Ask a question

Russian cell technology of skin rejuvenation received acknowledgement of the world scientific community

In December 2014, the Journal of Tissue Engineering and Regenerative Medicine (Impact factor 4.42) published the results of clinical trials of the cell technology termed the SPRS therapy: "Clinical-instrumental and Morphological Evaluation of the Effect of Autologous Dermal Fibroblasts Administration" (Zorin V., Zorina A., Cherkasov V., Deev R., Kopnin P., and Isaev A.). 

Briefly, the SPRS therapy is based on the use of patient's own (autologous) dermal fibroblasts to correct the age-related and structural changes of patient's skin. The technology has been developed at the Human Stem Cells Institute (HSCI), the Russian biotechnological company. In 2009 the technology was approved by RF Roszdravnadzor. The technology is protected by three Russian patents and one US patent. Since 2011, the SPRS therapy has been applied in Moscow leading dermatological and cosmetological clinics for patients of 35 to 65 years old. 

A small skin sample (bioptate) is taken behind patient's ear. This skin sample is used to obtain fibroblasts at the HSCI laboratory. Then, according to the ingenious procedure, the fibroblasts are cultivated for 6 – 7 weeks on special growth media to obtain the required amount and then are injected to the patient into the problem skin regions. The injected fibroblasts produce collagen, elastin, hyaluronic acid, and the other skin components; restore the skin microstructure, and stimulate natural processes of skin rejuvenation. As a result, the skin thickness, firmness, and elasticity are increased; whereas the skin surface is smoothened, the amount and depth of wrinkles are decreased, and the face color and contour are improved. 

The study results on this technology that were published in the international journal have been obtained by means of modern instrumental procedures. The studies have demonstrated the clinical efficiency and safety of the SPRS therapy. It has been shown that after transplantation the cultivated autologous fibroblasts are entirely integrated into the skin, completely retain their biosynthetic activity, and produce the dermal components at least for 12 months. As a result, remodeling of the skin structure is observed, which is accompanied by the increase of collagen level and derma thickness (in average by 63% for 12 months). 

The previously published data on two-year clinical trials of the SPRS therapy (in the journal "Clinical Dermatology and Venerology," N 3, 2013) have demonstrated that the clinical effect of this technology was constantly increased for 12 months after injections and retained at least for 2 years.